Natixis Advisors LLC Boosts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Natixis Advisors LLC boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 51.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 288,443 shares of the medical research company’s stock after buying an additional 98,554 shares during the quarter. Natixis Advisors LLC’s holdings in Edwards Lifesciences were worth $21,353,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences in the fourth quarter valued at $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC boosted its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new position in Edwards Lifesciences in the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 2.0 %

Shares of Edwards Lifesciences stock opened at $70.67 on Tuesday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $41.55 billion, a PE ratio of 10.14, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a 50-day moving average of $71.68 and a two-hundred day moving average of $70.34.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,303 shares of company stock valued at $3,715,776. Corporate insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of several research analyst reports. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Truist Financial restated a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Citigroup upped their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.